Dashboard
Manage Tickers

FDMT4D Molecular Therapeutics, ...

Nasdaq 4dmoleculartherapeutics.com


$ 14.98 $ 0.49 (3.39 %)    

Friday, 23-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 14.96
$ 14.96 x 300
-- x --
-- - --
$ 9.44 - $ 36.25
292,103
na
831.07M
$ 1.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-4d-molecular-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on 4D M...
08/09/2024 21:28:30

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...

4d-molecular-therapeutics-q2-eps-063-beats-071-estimate-sales-500k-down-from-23900k-yoy
4D Molecular Therapeutics Q2 EPS $(0.63) B...
08/08/2024 21:56:45

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimat...

rbc-capital-reiterates-outperform-on-4d-molecular-therapeutics-maintains-40-price-target
RBC Capital Reiterates Outperform on 4D Mo...
07/22/2024 13:56:12

RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...

why-dominos-pizza-shares-are-trading-lower-by-over-11-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Domino's Pizza Shares Are Trading Lowe...
07/18/2024 17:19:11

peeling-back-the-layers-exploring-4d-molecular-therapeutics-through-analyst-insights
Peeling Back The Layers: Exploring 4D Mole...
07/18/2024 14:00:34

bmo-capital-maintains-outperform-on-4d-molecular-therapeutics-lowers-price-target-to-40
BMO Capital Maintains Outperform on 4D Mol...
07/18/2024 13:21:57

BMO Capital analyst Kostas Biliouris maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the pric...

chardan-capital-maintains-buy-on-4d-molecular-therapeutics-maintains-38-price-target
Chardan Capital Maintains Buy on 4D Molecu...
07/17/2024 19:02:35

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $38 price...

4d-molecular-therapeutics-goes-neck-to-neck-with-rival-shares-new-phase-2-data-for-its-wet-amd-candidate
4D Molecular Therapeutics Goes Neck To Nec...
07/17/2024 18:22:23

4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-...

why-aslan-pharmaceuticals-shares-are-trading-lower-by-over-38-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why ASLAN Pharmaceuticals Shares Are Tradi...
07/17/2024 17:28:51

4d-molecular-therapeutics-presents-phase-2-trial-results-for-wet-amd-at-asrs-meeting
4D Molecular Therapeutics Presents Phase 2...
07/17/2024 09:02:01

4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)))), a leading clinical-stage genetic medicines company focused on ...

assessing-4d-molecular-therapeutics-insights-from-7-financial-analysts
Assessing 4D Molecular Therapeutics: Insig...
06/26/2024 16:00:14

rbc-capital-reiterates-outperform-on-4d-molecular-therapeutics-maintains-40-price-target
RBC Capital Reiterates Outperform on 4D Mo...
06/26/2024 15:14:25

RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...

4dmt-reports-fda-clearance-of-ind-application-for-4d-175-genetic-medicine-for-treatment-of-geographic-atrophy
4DMT Reports FDA Clearance Of IND Applicat...
06/24/2024 12:04:18

4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functi...

4d-molecular-therapeutics-to-present-24-week-interim-data-for-prism-phase-2-trial-of-4d-150-at-asrs-annual-meeting-webcast-scheduled-for-july-17-2024-at-630-am-et-to-discuss-safety-and-clinical-activity-updates
4D Molecular Therapeutics to Present 24-We...
06/18/2024 12:19:37

24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be p...

reported-saturday-4dmt-presented-injection-free-subgroup-analyses-from-4d-150-phase-2-prism-randomized-dose-expansion-cohort-in-wet-amd-patients-with-severe-disease-activity--high-treatment-burden-at-the-clinical-trials-summit-2024
Reported Saturday, 4DMT Presented Injectio...
06/10/2024 07:23:18

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF inj...

4d-molecular-therapeutics-entered-into-a-sales-agreement-with-leerink-partners-pursuant-to-prospectus-supplement-relating-to-offering-co-may-sell-up-to-250m-of-common-stock
4D Molecular Therapeutics Entered Into A S...
06/07/2024 21:19:40

- SEC Filing

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside
Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

analyst-expectations-for-4d-molecular-therapeuticss-future
Analyst Expectations For 4D Molecular Ther...
06/07/2024 15:00:39

hc-wainwright--co-reiterates-buy-on-4d-molecular-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on 4D M...
06/07/2024 13:46:39

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...

why-g-iii-apparel-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why G-III Apparel Shares Are Trading Lower...
06/06/2024 17:39:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION